Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sagent Pharmaceuticals (SGNT) Numbers Cut at Piper Jafffray Post Q2
August 5, 2015 9:47 AM EDTPiper Jaffray analyst David Amsellem lowered his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $32.00 (from $35.00) following Q2 results but maintained an Overweight rating.
Amsellem commented, "This morning, Sagent reported a 2Q15 net loss per share of ($0.01), compared to the Street EPS... More
RBC Capital Upgrades Sagent Pharmaceuticals (SGNT) to Outperform
August 4, 2015 11:17 AM EDTRBC Capital upgraded Sagent Pharmaceuticals (NASDAQ: SGNT) from Sector Perform to Outperform.
For an analyst ratings summary and ratings history on Sagent Pharmaceuticals click here. For more ratings news on Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $25.11 yesterday.
... More